Actoplus Met XR is a Oral Tablet, Film Coated, Extended Release in the Human Prescription Drug category. It is labeled and distributed by Takeda Pharmaceuticals America, Inc.. The primary component is Pioglitazone Hydrochloride; Metformin Hydrochloride.
| Product ID | 64764-310_12f6dfdd-309c-44a9-86bf-664c449f5ddb |
| NDC | 64764-310 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Actoplus Met XR |
| Generic Name | Pioglitazone And Metformin Hydrochloride |
| Dosage Form | Tablet, Film Coated, Extended Release |
| Route of Administration | ORAL |
| Marketing Start Date | 2010-06-11 |
| Marketing End Date | 2022-09-30 |
| Marketing Category | NDA / NDA |
| Application Number | NDA022024 |
| Labeler Name | Takeda Pharmaceuticals America, Inc. |
| Substance Name | PIOGLITAZONE HYDROCHLORIDE; METFORMIN HYDROCHLORIDE |
| Active Ingredient Strength | 30 mg/1; mg/1 |
| Pharm Classes | Peroxisome Proliferator-activated Receptor Activity [MoA],PPAR alpha [CS],PPAR gamma [CS],Thiazolidinedione [EPC],Thiazolidinediones [CS],Peroxisome Proliferator Receptor alpha Agonist [EPC],Peroxisome Proliferator Receptor gamma Agonist [EPC],Biguanide [EPC],Biguanides [CS] |
| NDC Exclude Flag | N |
| Marketing Start Date | 2010-06-11 |
| Marketing End Date | 2022-09-30 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA022024 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2010-06-11 |
| Marketing End Date | 2022-09-30 |
| Marketing Category | NDA |
| Application Number | NDA022024 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2010-06-11 |
| Marketing End Date | 2022-09-30 |
| Marketing Category | NDA |
| Application Number | NDA022024 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2010-06-11 |
| Marketing End Date | 2022-09-30 |
| Marketing Category | NDA |
| Application Number | NDA022024 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2010-06-11 |
| Marketing End Date | 2022-09-30 |
| Marketing Category | NDA |
| Application Number | NDA022024 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2010-06-11 |
| Marketing End Date | 2022-09-30 |
| Ingredient | Strength |
|---|---|
| PIOGLITAZONE HYDROCHLORIDE | 30 mg/1 |
| SPL SET ID: | f986164c-51a7-41c2-8952-511b8f46d593 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | |
| UPC Code |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 64764-155 | Actoplus Met | pioglitazone and metformin hydrochloride |
| 64764-158 | Actoplus Met | pioglitazone and metformin hydrochloride |
| 64764-310 | Actoplus Met | pioglitazone and metformin hydrochloride |
| 64764-510 | Actoplus Met | pioglitazone and metformin hydrochloride |
| 0093-7677 | Pioglitazone and Metformin Hydrochloride | Pioglitazone and Metformin Hydrochloride |
| 0093-7678 | Pioglitazone and Metformin Hydrochloride | Pioglitazone and Metformin Hydrochloride |
| 42291-512 | Pioglitazone and Metformin Hydrochloride | Pioglitazone and Metformin Hydrochloride |
| 42291-513 | Pioglitazone and Metformin Hydrochloride | Pioglitazone and Metformin Hydrochloride |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() ACTOPLUS MET 78218773 3149378 Live/Registered |
TAKEDA PHARMACEUTICAL COMPANY LIMITED 2003-02-25 |
![]() ACTOPLUS MET 78174989 not registered Dead/Abandoned |
Takeda Chemical Industries, Ltd. 2002-10-16 |